At MEDsan Inc. our focus is always on our clients. We understand that every individual is unique, which is why we take the time to listen to their concerns and tailor our services to meet their individual needs. That is why we concentrate on Research & Development, testing extensively with latest technologies available, and on developing innovative and unique immunobiological drugs and high quality supplements to achieve:

• Neutralization of pathologically growing cells
• Prevention of tumor cell colonization
• Destruction of fungi
• Regulative effect on allergic and autoreactive processes
• Stimulation of non-specific and specific immune system
• Stimulation of stem cells
• Stimulation of well-being

So let's start with:

• Prevention as it is the best therapy and looking at what role genetics play...
• Understanding that every human is unique. Unique in appearance, but also in terms of absorption and effects of medication.
• Testing preventatively to diagnose, as an example, tumors at an early stage or even better before they grow, as the chance of surviving 5 years and more increases to 80% - 100%.
• Understanding that genetic changes can also increase the risk of sudden cardiac death.
• Accepting that genetics play a central role in the development of familial diabetes mellitus.
• Agreeing that early identification of genetic risk factors and timely intervention can prevent or delay the onset or progression of a disease.
• Acknowledging that every 7th person has a genetic predisposition to diseases against which preventive measures can be taken!

We are proud to be accredited by CLIA through COLA. COLA accredits nearly 8,000 medical laboratories and provides the clinical laboratory with a program of education, consultation, and accreditation. The organization is an independent, non-profit accreditor whose education based program and standards enable clinical laboratories and staff to meet U.S. CLIA and other regulatory requirements.The Clinical Laboratory Improvement Amendments of 1988 (CLIA) regulations include federal standards applicable to all U.S. facilities or sites that test human specimens for health assessment or to diagnose, prevent, or treat disease. CDC (Centers for Disease Control and Prevention), in partnership with CMS and FDA, supports the CLIA program and clinical laboratory quality.We also have a National Provider Identifier (NPI), issued in the United States by the Centers of Medicare and Medicaid Services (CMS). We take pride of accepting CMS, any kind of Health Care Insurance Program, and self insurance/self pay.